Mead Johnson Nutrition Company (NYSE: MJN) has reached the end of its analyst quiet period where the firms who underwrote the deal can now begin their ratings coverage. This was the Bristol-Myers Squibb Co. (NYSE: BMY) spin off. If you will recall, Citigroup and Morgan Stanley were the joint book-runners on the deal. Banc of America, Credit Suisse, J.P.Morgan, RBC, UBS, and Lazard were the co-managers of the underwriting. These are the calls we have seen far for New analyst coverage initiations:
- ‘Buy’ at Citigroup (joint book-runner)
- ‘Equal Weight’ at Morgan Stanley (joint book-runner)
- ‘Outperform’ at RBC Capital
- ‘Neutral’ at B of A Merrill
- ‘Neutral’ at JPMorgan
- ‘Neutral’ at Credit Suisse
This is still up about 10% since its IPO in early February.
JON C. OGG
March 23, 2009
